Drug Trial Radar · NCT07613567
QL1706 Combined With Chemotherapy as Neoadjuvant Therapy for High-Risk Locally Advanced Cervical Cancer
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
486
Planned (sponsor's estimate)
Start
Jan 1, 2027
Primary completion
Dec 31, 2032
Study completion Dec 31, 2032
Sponsor
- Lead sponsor
- Fujian Cancer HospitalGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- First posted
- May 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to compare the efficacy and safety of "neoadjuvant immunotherapy combined with chemotherapy followed by immunotherapy combined with radiotherapy during the radiotherapy period" versus "standard concurrent chemoradiotherapy" in locally advanced cervical cancer.
Conditions
- Locally Advanced Cervical Carcinoma
Interventions
standard EBRT+BrachytherapyRadiation
EBRT: 45-50.4Gy, Brachytherapy: 6Gy ×5
CisplatinDrug
Cisplatin 40mg/m2, qw×5
Neoadjuvant chemoimmunotherapyDrug
Neoadjuvant phase: total of 2 cycles. Iparomlimab/Tuvonralimab 5mg/kg,D1,Q3W + albumin paclitaxel 90mg/m2, D1、8、15,Q3W+ Cisplatin 25mg/m2 or Carboplatin AUC = 1.5 , D1、8、15,Q3W
Radiotherapy combined with immunotherapyRadiation
Following neoadjuvant therapy, patients will receive EBRT + QL1706. After EBRT completion, brachytherapy dose is 600 cGy × 3 fractions for patients with clinical complete response (CCR), and 600 cGy × 5 fractions for non-CCR patients.
Immunomaintenance therapyDrug
Iparomlimab/Tuvonralimab (QL1706) 5 mg/kg,D1,Q3W. Will be administered for up to 2 years, until disease progression, or until unacceptable toxicity, whichever occurs first.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival(PFS)Time frame: Up to approximately 60 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fujian Cancer Hospital
Fuzhou, Fujian, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.